WuXi XDC Demonstrates Strong Financial Performance
WuXi XDC Cayman Inc., a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in bioconjugates, has shown remarkable growth in its financial performance. The company reported a year-on-year revenue increase of 62.2%, reaching RMB 2,701 million. This impressive growth reflects the strong demand for its services in the bioconjugates market.
Explosive Growth in Gross Profit
The gross profit of WuXi XDC surged by 82.2% YoY to RMB 975 million, indicating a robust gross profit margin of 36.1%. This substantial growth is primarily attributed to improved operational efficiencies, increasing customer demand, and successful project developments across its services.
Net Profit Growth Highlights
Adjusted net profit before interest and expenses increased by 69.6% YoY, reaching RMB 733 million with a margin of 27.1%. Including interest income and expenses, the adjusted net profit also rose by 50.1% YoY to RMB 801 million, reaffirming the company’s strong financial foundation.
Client Base Expansion and Market Positioning
WuXi XDC’s total customer base grew significantly, now totaling 563 clients, which includes a substantial number of top pharmaceutical companies around the globe. In the first half of 2025, the company added 64 new customers, demonstrating its increasing influence and leadership in the bioconjugate sector.
Rapidly Growing iCMC Projects
The total number of integrated CMC (iCMC) projects reached 225, marking an increase with 37 newly signed agreements in the first half of 2025. This growth is crucial in maintaining WuXi XDC’s competitive edge, specially tailored to meet the evolving needs of its clientele.
Innovative Technology and Capacity Expansion
As part of its commitment to innovation, WuXi XDC continues to invest in frontier technologies that empower clients to explore new modalities in drug development. The Group’s capacity expansion includes critical milestones at its facilities, enabling larger-scale manufacturing capabilities.
Achievements at the Manufacturing Facilities
The DP3 facility at WuXi XDC’s primary site obtained GMP release, highlighting the Group's capabilities in advanced manufacturing processes. The Singapore site has also made substantial progress and is on track for GMP release expected in the future.
Acknowledgments and Future Outlook
WuXi XDC's excellence in operations has not gone unnoticed; the company has received multiple prestigious awards recognizing its leadership and effectiveness in corporate governance and investor relations. Looking forward, WuXi XDC remains dedicated to sustaining its growth trajectory and enhancing its support for clients in the bioconjugates domain.
Frequently Asked Questions
What is WuXi XDC's revenue growth for the first half of 2025?
WuXi XDC's revenue grew by 62.2% YoY, totaling RMB 2,701 million in the first half of 2025.
How has WuXi XDC's gross profit changed?
The gross profit increased by 82.2% YoY to RMB 975 million, reflecting a robust gross profit margin of 36.1%.
What is the total number of customers for WuXi XDC?
WuXi XDC has expanded its customer base to 563 clients, adding 64 new customers in the first half of the year.
How many iCMC projects has WuXi XDC initiated?
The company reported a total of 225 iCMC projects, with 37 new projects signed in the first half of 2025.
What technological advancements is WuXi XDC pursuing?
WuXi XDC continues to invest in innovative technologies to enhance drug development processes, including expanded manufacturing capabilities in key facilities.
